The DOI matches its Crossref record.
COX‐2 selective NSAID decreases bone ingrowth in vivo
Open accessAbstract
Whether non‐steroidal anti‐inflammatory drug (NSAID)—induced suppression of bone ingrowth is due to cyclooxygenase‐1 (COX‐1) inhibition, cyclooxygenase‐2 (COX‐2) inhibition, or through a yet unidentified pathway is unknown. In this study, the effects of a non‐specific COX‐1 and COX‐2 inhibitor, versus a specific COX‐2 inhibitor on bone ingrowth and tissue differentiation are examined in vivo. Harvest chambers were implanted unilaterally in the tibiae of eight mature, New Zealand white rabbits. After a 6‐week period for osseointegration of the chamber, the following oral treatments were given for 4 weeks each, followed by a harvest in each case: drinking water with no NSAID (control 1), Naproxen sodium–a COX‐1 and COX‐2 non‐specific inhibitor at a dose of 110 mg/kg/day in the drinking water, drinking water with no NSAID (control 2), and Rofecoxib—a COX‐2 inhibitor at a dose of 12.5 mg/day inserted directly into the rabbit's mouth. Harvested specimens were snap frozen, cut into serial 6 μm sections and stained with hematoxylin and eosin for general morphological characterization, and alkaline phosphatase (osteoblast marker). Sections were also processed for immunoperoxidase staining using monoclonal antibodies to identify cells expressing the vitronectin receptor (osteoclast‐like cells). With drinking water alone, the percentage of bone ingrowth averaged 24.8 ± 2.9% and 29.9 ± 4.5% respectively. Naproxen sodium in the drinking water and oral Rofecoxib decreased bone ingrowth significantly (15.9 ± 3.3%, p = 0.031 and 18.5 ± 2.4%, p = 0.035 compared to drinking water respectively). Both Naproxen sodium (p = 0.026) and Rofecoxib (p = 0.02) decreased the number of CD51 positive osteoclast‐like cells per section compared with drinking water alone. Rofecoxib decreased the area of osteoblasts per section area (p = 0.014) compared to controls, although the value for Naproxen sodium did not reach statistical significance. The results of the present study suggest that bone formation is suppressed by oral administration of an NSAID which contains a COX‐2 inhibitor. COX‐2 inhibitors currently taken for arthritis and other conditions may potentially delay fracture healing and bone ingrowth. © 2002 Orthopaedic Research Society. Published by Elsevier Science Ltd. All rights reserved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
Warner, T. D., & Mitchell, J. A. (2004) · The FASEB Journal · doi:10.1096/fj.03-0645rev · Cited by 614
Do Nonsteroidal Anti-Inflammatory Drugs Affect Bone Healing? A Critical Analysis
Pountos, I., Georgouli, T., Calori, G. M., & Giannoudis, P. V. (2012) · The Scientific World Journal · doi:10.1100/2012/606404 · Cited by 274
Pharmacological agents and impairment of fracture healing: What is the evidence?
Pountos, I., Georgouli, T., Blokhuis, T. J., Pape, H. C., & Giannoudis, P. V. (2008) · Injury · doi:10.1016/j.injury.2007.10.035 · Cited by 168
Harder, A. T., & An, Y. H. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003256061 · Cited by 155
Effects of cyclooxygenase inhibition on bone, tendon, and ligament healing
Radi, Z. A., & Khan, N. K. (2005) · Inflammation Research · doi:10.1007/s00011-005-1367-4 · Cited by 113
Metadata
- Authors
- Goodman, S., Ma, T., Trindade, M., Ikenoue, T., Matsuura, I., Wong, N., Fox, N., Genovese, M., Regula, D., & Smith, R. L.
- Venue
- Journal of Orthopaedic Research
- Publisher
- Wiley
- Published
- 2002-11
- Volume
- 20
- Issue
- 6
- Pages
- 1164-1169
- ISSN
- 0736-0266 (ISSN-L)
- 1554-527X
- OpenAlex
- W2014363460
- Cited by
- 174
- References
- 0
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COX‐2 selective NSAID decreases bone ingrowth in vivo. https://app.cochat.ai/papers/10.1016/s0736-0266(02)00079-7
- The paper
- Goodman, S., Ma, T., Trindade, M., Ikenoue, T., Matsuura, I., Wong, N., Fox, N., Genovese, M., Regula, D., & Smith, R. L. (2002). COX‐2 selective NSAID decreases bone ingrowth in vivo. Journal of Orthopaedic Research. https://doi.org/10.1016/s0736-0266(02)00079-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.